Canopy Growth Corporation — Form 10-Q Summary
Reporting period: Three and nine months ended December 31, 2021 (fiscal 2022 Q3). The filing was signed February 9, 2022. Financial amounts are in Canadian dollars; figures below are in millions unless stated otherwise.
Business context
Canopy Growth produces and sells cannabis and cannabinoid products in Canada and international markets, alongside consumer products including Storz & Bickel vaporizers, This Works products and BioSteel sports nutrition. It reports two segments: global cannabis and other consumer products. During the period, it acquired Supreme Cannabis and Ace Valley and agreed to options to acquire Wana if U.S. federal law changes to permit the relevant cannabis activities.
Key financial metrics
| Metric | Three months ended Dec. 31, 2021 | Prior-year quarter | Nine months ended Dec. 31, 2021 | Prior-year period |
|---|---|---|---|---|
| Net revenue | $141.0 | $152.5 | $408.6 | $398.2 |
| Gross margin | $10.1 | $24.6 | $(33.8) | $57.2 |
| Gross margin percentage | 7% | 16% | (8%) | 14% |
| Operating loss | $(150.0) | $(553.6) | $(553.0) | $(1,010.3) |
| Net income (loss) | $(115.5) | $(829.3) | $258.1 | $(1,054.1) |
| Adjusted EBITDA loss (non-GAAP) | $(67.4) | $(68.4) | $(293.7) | $(246.3) |
| Cash used in operating activities | $(167.4) | $(87.6) | $(419.1) | $(367.9) |
| Free cash flow (non-GAAP) | $(168.3) | $(135.4) | $(455.7) | $(505.9) |
At December 31, 2021, cash and cash equivalents were $615.1 and short-term investments were $807.9, totaling about $1.42 billion. Total debt carrying value was approximately $1.51 billion, including $15.7 current and $1,494.7 long-term. The secured US$750 million term loan matures in 2026, carries interest at LIBOR plus 8.50% (with a 1.00% floor), and requires minimum quarterly liquidity of US$200 million. The company reported $40 million of capacity under its FCC revolving facility and the ability to seek up to US$500 million of incremental secured debt under the credit agreement.
Material changes and unusual items
- Quarterly net revenue fell 8%, as global cannabis revenue declined 20% to $83.0 million; other consumer products revenue rose 19% to $58.0 million. BioSteel quarterly revenue increased 131% to $17.0 million.
- Canadian recreational cannabis revenue declined amid inadequate supply of in-demand flower products, price compression and increased retail competition. C3 revenue also fell amid competition, pricing pressure and COVID-related sales limitations in Germany.
- Nine-month revenue grew 3%, but gross margin turned negative, primarily because of inventory write-downs. Inventory write-downs recorded in cost of goods sold were $104.7 million for the nine months, compared with $48.2 million a year earlier.
- Nine-month net income of $258.1 million was heavily affected by $810.8 million of other income, net, primarily non-cash fair-value gains on the Acreage arrangement and CBI warrant liability. These valuation-sensitive gains should not be read as operating cash generation. The company still reported a nine-month Adjusted EBITDA loss of $293.7 million.
- Cash and cash equivalents declined $539.5 million from March 31, 2021. Nine-month operating cash use increased to $419.1 million, partly reflecting lower gross margin and higher interest paid; investing cash use was $71.1 million and financing cash use was $46.3 million.
- The company recorded $128.2 million of nine-month asset impairment and restructuring costs and closed or planned closures of Canadian production sites. Cannabis goodwill was not impaired at December 31, but its estimated fair value exceeded carrying value by only about 15%–20%.
Outlook, risks and contingencies
Management said available cash, investments and financing capacity should fund working capital, growth initiatives, capital expenditure, liabilities and scheduled debt payments for at least the next 12 months. It also cautioned that there is no assurance of sufficient product acceptance or positive cash flow to execute its plans. The filing provides no quantified revenue, earnings or cash-flow guidance.
Key risks include continued cannabis price compression and competition, demand and inventory forecasting, possible further impairment, regulatory uncertainty—particularly the timing and terms of U.S. federal cannabis-law changes—foreign exchange and interest-rate exposure, and pandemic-related or broader supply-chain disruption. Management said COVID-19 had not materially adversely affected Q3 results, but future effects remained uncertain.
- Wana: Canopy paid $368.1 million upfront for options to acquire the business following a qualifying U.S. federal-law change. Further call-option and deferred payments may be due; Canopy currently has no ownership or control of Wana.
- C3 divestiture: Completed January 31, 2022 for $128.3 million cash, including adjustments, with potential earnout of up to €42.6 million.
- Legal matter: Canopy reached an agreement to settle a U.S. securities class action; preliminary court approval had been granted, but final approval and other terms remained outstanding. The company denied wrongdoing.
- Acreage arrangement: Acquisition depends on a U.S. federal-law Triggering Event and other conditions; its reported liability is fair-value sensitive.
Most important facts for investors to verify
- Whether cash burn moderates and reported liquidity remains sufficient, including compliance with the US$200 million quarterly minimum-liquidity covenant.
- Whether cannabis inventory write-downs, product availability and pricing improve, and what gross margins look like excluding temporary or acquisition-related effects.
- How much of reported earnings comes from non-cash fair-value movements versus operating performance and cash generation.
- The carrying value and impairment headroom of cannabis goodwill, especially given the disclosed 15%–20% fair-value cushion.
- The full potential cash or share obligations under the Wana options and deferred payments, and the conditions and proceeds associated with the C3 sale and earnout.
- The final approval and financial terms of the securities-class-action settlement, as well as developments affecting U.S. cannabis legalization and the Acreage arrangement.